Vanda Pharmaceuticals (VNDA) Interest Coverage Ratio (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Interest Coverage Ratio of 6.32 for Q1 2026, up 57.75% sequentially from 14.96 in Q4 2025, and down 7.92% YoY from 6.86 in Q1 2025.
Vanda Pharmaceuticals (VNDA) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Interest Coverage Ratio for 17 years, with the latest figure at 6.32 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 7.92% year-over-year to 6.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.18 (down 95.13% YoY) and the FY2025 annual result came in at 1.22, up 73.44% from the prior year.
- Interest Coverage Ratio improved to 6.32 in Q1 2026 per VNDA's latest filing, from 14.96 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 1.69 in Q3 2022 and troughed at 14.96 in Q4 2025.
- A 5-year average of 2.75 and a median of 1.57 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio surged 231.39% in 2022, then sank 1193.12% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 0.93 in 2022, then sank by 189.35% to 0.83 in 2023, then slumped by 39.35% to 1.16 in 2024, then tumbled by 1193.12% to 14.96 in 2025, then jumped by 57.75% to 6.32 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 6.32, 14.96, and 4.46 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -8.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.03 |
| Mar 31, 2026 | -6.32 |
| Dec 31, 2025 | -14.96 |
| Sep 30, 2025 | -4.46 |
| Jun 30, 2025 | -5.49 |
| Mar 31, 2025 | -5.86 |
| Dec 31, 2024 | -1.16 |
| Sep 30, 2024 | -1.57 |
| Jun 30, 2024 | -1.45 |
| Mar 31, 2024 | -1.32 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -4.10 |
| Jun 30, 2023 | -1.89 |
| Mar 31, 2023 | 1.32 |
| Dec 31, 2022 | 0.93 |
| Sep 30, 2022 | 1.69 |
| Jun 30, 2022 | 1.31 |
| Mar 31, 2022 | -2.53 |
| Dec 31, 2021 | 1.23 |
| Sep 30, 2021 | 0.63 |